Soluble CD44 is a promising biomarker with a prognostic value in breast cancer patients | ||||
| Egyptian Journal of Cancer and Biomedical Research | ||||
| Article 8, Volume 5, Issue 3, September 2021, Page 77-86 PDF (1.31 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jcbr.2020.45460.1076 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Sanaa El-benhawy  1; Samia Ebeid2; Nadia Abd El Moneim3; Ahmed Ahmed4; Sanaa S Ahmed5; Hassan Wezza6
| ||||
| 1Radiation Sciences Department, Medical Research Institute, Alexandria University, Alexandria, Egypt. | ||||
| 2Applied Medical Chemistry Department, Medical Research Institute, Alexandria University, Alexandria, Egypt. | ||||
| 3Cancer Management and Research Department, Medical Research Institute, Alexandria University, Alexandria, Egypt. | ||||
| 4Experimental and Clinical Surgery Department, Medical Research Institute, Alexandria University, Alexandria, Egypt. | ||||
| 5Pathology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt. | ||||
| 6Applied Medical Chemistry Department, Medical Research Institute, Alexandria University, Alexandria, Egypt. | ||||
| Abstract | ||||
| Background: Cancer is a heterogeneous disease encompassing various subtypes. Exploration of novel biomarkers is important to tailor therapy. Aim: The main aim of this study was toexplore the prognostic value of soluble CD44 in the sera of breast cancer patients (BCPs), and to correlate its levels with hyaluronic acid (HA), VEGF and p53 levels. Subjects and Methods: Fifty female BCPs were enrolled in the study as a patient group and 50 healthy females as a control group. Cancerous and neighboring normal breast tissues were collected from BCPs. Blood samples were collected from BCPs at diagnosis and control group. CD44 tissue expression was evaluated by immunohistochemistry (IHC). Serum levels of sCD44, HA, VEGF, and p53levels were measured by ELISA. Results: CD44 showed high expression in cancerous breast tissues as compared to control tissues. Circulating sCD44 was highly increased in BCPs and was associated significantly with the expression levels of CD44 in tissues. Serum HA and VEGF levels were highly elevated in BCPs along with the increase in CD44 positivity. In contrast, the decrease in p53 level was associated with higher CD44 expression in BCPs. According to Kaplan-Meier curves, BCPs who expressed high levels of sCD44 or tissue CD44 showed shorter DFS time than CD44 negative. Conclusion: Tissue and soluble CD44 are significantly elevated in BCPs and associated with increases in HA and VEGF. Increased sCD44 is related to bad patients' survival. As such, CD44 can be used as a prognostic marker in breast cancer patients. | ||||
| Keywords | ||||
| Breast cancer; CD44; Hyaluronic acid; p53; VEGF | ||||
|
Statistics Article View: 430 PDF Download: 248 |
||||
